By investing across public and private markets, Foresite creates a positive feedback loop. Understanding what public investors value (e.g., product-centric assets for unmet needs like pancreatic cancer) directly influences the firm's strategy for incubating and building new companies from scratch.
A hedge fund's focus on yearly performance incentivizes betting on short-term catalysts, like clinical data events. In contrast, a venture capital fund's typical 10-year lockup period allows it to ignore market cycles and underwrite the best science for a long-term outcome.
While investing in a crowded therapeutic space feels safer, returns are capped. A high-risk area like pancreatic cancer offers a better investment profile. A 50% chance of a 10x upside yields a 5x probability-adjusted return, outperforming a crowded space with an 80% chance of a 2x return.
The Fed lowering interest rates, as seen during COVID, makes capital cheap and pushes investors toward riskier assets like biotech to chase yield. This floods the market with capital, enabling even preclinical companies to go public—a trend that reverses sharply when rates rise.
The blockbuster success of GLP-1 weight-loss drugs creates a large unmet need. Since these drugs cause significant loss of both fat and muscle, there is a massive emerging market for adjunctive therapies that can specifically build or preserve muscle mass in this growing patient population.
The business model for psychedelic medicine hinges on clinic time. Long-acting drugs like psilocybin or LSD require an 8-hour session, creating a logistical and cost burden. Therapies with shorter experiences, like DMT's 30-minute window, offer a significant advantage in patient convenience and clinic throughput.
Fifteen years ago, investors could gain an edge through information asymmetry, like spotting an FDA approval before a press release. Today, with markets on a level playing field, success hinges on deep technical analysis of a drug's scientific viability, making it a specialist's game.
Observing hype around CAR-T for autoimmune diseases, Foresite recognized its commercial impracticality for non-oncology patients. They hypothesized that off-the-shelf T-cell engagers could achieve similar results with better convenience, leading them to incubate Candid Therapeutics, which UCB acquired for $2B.
A massive influx of capital into Chinese biotech, followed by a public market slowdown, left many innovative companies "trapped" without funding. This created a unique opportunity for Western pharma and VCs to license high-quality assets, driving pharma's China deal volume from single digits to nearly 50%.